

Margaritis Avgeris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3418248/publications.pdf>

Version: 2024-02-01

65
papers

2,004
citations

257101

24
h-index

264894

42
g-index

65
all docs

65
docs citations

65
times ranked

3436
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | <scp>Epiâ€miRNAs</scp>: Modern mediators of methylation status in human cancers. Wiley Interdisciplinary Reviews RNA, 2023, 14, e1735. | 3.2 | 5 |
| 2 | SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. Science of the Total Environment, 2022, 804, 150151. | 3.9 | 116 |
| 3 | miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. British Journal of Cancer, 2022, 126, 79-90. | 2.9 | 11 |
| 4 | tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. Cancers, 2022, 14, 24. | 1.7 | 25 |
| 5 | Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. TrAC - Trends in Analytical Chemistry, 2021, 134, 116125. | 5.8 | 88 |
| 6 | Impact of three-dimensional vision in laparoscopic partial nephrectomy for renal tumors. Turkish Journal of Urology, 2021, 47, 144-150. | 1.3 | 3 |
| 7 | Jagged Ends of Cell-Free DNA: Rebranding Fragmentomics in Modern Liquid Biopsy Diagnostics. Clinical Chemistry, 2021, 67, 576-578. | 1.5 | 3 |
| 8 | Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in â€œImmune Desertâ€•NSCLC. Cancers, 2021, 13, 1658. | 1.7 | 5 |
| 9 | Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. Cancers, 2021, 13, 2446. | 1.7 | 5 |
| 10 | A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 2021, 13, 3877. | 1.7 | 12 |
| 11 | Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. International Journal of Molecular Sciences, 2021, 22, 8498. | 1.8 | 11 |
| 12 | A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144. | 1.8 | 13 |
| 13 | Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL. Cancers, 2021, 13, 6064. | 1.7 | 5 |
| 14 | miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. Carcinogenesis, 2020, 41, 442-451. | 1.3 | 10 |
| 15 | tRNA-Derived Fragments (tRFs) in Bladder Cancer: Increased 5â€™-tRF-LysCTT Results in Disease Early Progression and Patientsâ€™ Poor Treatment Outcome. Cancers, 2020, 12, 3661. | 1.7 | 31 |
| 16 | Seafood mislabeling in Greek market using DNA barcoding. Food Control, 2020, 113, 107213. | 2.8 | 23 |
| 17 | miR-181a overexpression predicts the poor treatment response and earlyâ€•progression of serous ovarian cancer patients. International Journal of Cancer, 2020, 147, 3560-3573. | 2.3 | 7 |
| 18 | Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome. Diabetes Research and Clinical Practice, 2020, 164, 108187. | 1.1 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Circulating miR-146a and miR-134 in predicting drug-resistant epilepsy in patients with focal impaired awareness seizures. <i>Epilepsia</i> , 2020, 61, 959-970. | 2.6 | 35 |
| 20 | Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy. <i>Annals of Oncology</i> , 2019, 30, v462-v463. | 0.6 | 2 |
| 21 | ^{18}F -Np63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3075-3087. | 1.2 | 4 |
| 22 | Circulating exosomal miRNAs: clinical significance in human cancers. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 979-995. | 1.5 | 28 |
| 23 | The lysine-specific methyltransferase <i>KMT2C</i> / <i>MLL3</i> regulates DNA repair components in cancer. <i>EMBO Reports</i> , 2019, 20, . | 2.0 | 93 |
| 24 | HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. <i>PLoS ONE</i> , 2019, 14, e0215984. | 1.1 | 17 |
| 25 | Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer. <i>Carcinogenesis</i> , 2019, 40, 965-974. | 1.3 | 14 |
| 26 | Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 937. | 1.8 | 8 |
| 27 | Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291. | 1.8 | 47 |
| 28 | Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk. <i>Scientific Reports</i> , 2019, 9, 1512. | 1.6 | 21 |
| 29 | Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12. <i>Current Pharmaceutical Biotechnology</i> , 2019, 19, 1064-1075. | 0.9 | 10 |
| 30 | The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma. <i>Blood</i> , 2019, 134, 5529-5529. | 0.6 | 0 |
| 31 | Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2018, 97, 1169-1182. | 0.8 | 17 |
| 32 | miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 150-161. | 1.5 | 26 |
| 33 | Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1477-1486. | 2.9 | 41 |
| 34 | miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 963-979. | 1.5 | 41 |
| 35 | BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2104-2118. | 1.4 | 10 |
| 36 | Biomarkers with Prognostic Potential in Prostate Cancer. <i>Frontiers in Medicinal Chemistry</i> , 2018, , 108-34. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Combining of ETHOS Operating Ergonomic Platform, Three-dimensional Laparoscopic Camera, and Radius Surgical System Manipulators Improves Ergonomy in Urologic Laparoscopy: Comparison with Conventional Laparoscopy and da Vinci in a Pelvi Trainer. <i>European Urology Focus</i> , 2017, 3, 413-420. | 1.6 | 15 |
| 38 | miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 453-464. | 1.6 | 40 |
| 39 | miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. <i>British Journal of Cancer</i> , 2017, 117, 801-812. | 2.9 | 33 |
| 40 | Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. <i>Annals of Oncology</i> , 2017, 28, 2213-2218. | 0.6 | 12 |
| 41 | Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933. | 0.6 | 153 |
| 42 | Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 521-532. | 1.2 | 16 |
| 43 | Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 801-818. | 1.5 | 36 |
| 44 | Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 704-713. | 3.2 | 173 |
| 45 | Abstract 3108: PD-L1 expressing circulating tumor cells (CTCs) in patients with head and neck squamous cell carcinoma (HNSCC). , 2016, , . | | 3 |
| 46 | The prognostic significance of Notch 1 intracellular domain nuclear levels in head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6061-6061. | 0.8 | 0 |
| 47 | Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2023-2036. | 1.2 | 10 |
| 48 | Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. <i>Carcinogenesis</i> , 2015, 36, 528-537. | 1.3 | 67 |
| 49 | PDL1-expressing circulating tumor cells (CTCs) in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6018-6018. | 0.8 | 2 |
| 50 | Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel: retrospective analysis of EORTC24971 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6061-6061. | 0.8 | 0 |
| 51 | Targeting kallikrein-related peptidases in prostate cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 365-383. | 1.5 | 25 |
| 52 | Loss of miR-378 in prostate cancer, a common regulator of <i>KLK2</i> and <i>KLK4</i> , correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. <i>Biological Chemistry</i> , 2014, 395, 1095-1104. | 1.2 | 29 |
| 53 | A new tumor suppressor role for the Notch pathway in bladder cancer. <i>Nature Medicine</i> , 2014, 20, 1199-1205. | 15.2 | 160 |
| 54 | Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 39.e29-39.e36. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 2573-2581. | 2.9 | 90 |
| 56 | Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. <i>Biological Chemistry</i> , 2012, 393, 301-317. | 1.2 | 79 |
| 57 | L-Dopa decarboxylase (<i>DDC</i>) gene expression is related to outcome in patients with prostate cancer. <i>BJU International</i> , 2012, 110, E267-73. | 1.3 | 20 |
| 58 | Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (<i>KLK14</i>) in malignant and benign breast tissues. <i>Thrombosis and Haemostasis</i> , 2011, 105, 131-137. | 1.8 | 10 |
| 59 | Down-regulation of kallikrein-related peptidase 5 (<i>KLK5</i>) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. <i>Clinical Proteomics</i> , 2011, 8, 5. | 1.1 | 22 |
| 60 | Kallikrein-related peptidase 4 gene (<i>KLK4</i>) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. <i>Prostate</i> , 2011, 71, 1780-1789. | 1.2 | 28 |
| 61 | Expression analysis and study of the <i>KLK15</i> mRNA splice variants in prostate cancer and benign prostatic hyperplasia. <i>Cancer Science</i> , 2010, 101, 693-699. | 1.7 | 18 |
| 62 | Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. <i>Biological Chemistry</i> , 2010, 391, 505-511. | 1.2 | 75 |
| 63 | Expression analysis and study of <i>KLK4</i> in benign and malignant breast tumours. <i>Thrombosis and Haemostasis</i> , 2009, 101, 381-387. | 1.8 | 26 |
| 64 | Expression analysis and study of <i>KLK4</i> in benign and malignant breast tumours. <i>Thrombosis and Haemostasis</i> , 2009, 101, 381-7. | 1.8 | 10 |
| 65 | Expression analysis and clinical utility of L-Dopa decarboxylase (<i>DDC</i>) in prostate cancer. <i>Clinical Biochemistry</i> , 2008, 41, 1140-1149. | 0.8 | 37 |